Skip to content
10-K

Annual Report

LUMOS PHARMA, INC.

0001126234-24-000025

← back to feed
Filed
Mar 7, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2023 · Dec 31, 2023 8.15M sh
Shares Diluted FY 2023 · Dec 31, 2022 8.37M sh
Stock Repurchased FY 2023 · Dec 31, 2023 $1.31M
Stock Repurchased FY 2023 · Dec 31, 2022 $675K
Operating Cash Flow FY 2023 · Dec 31, 2023 −$31.1M
Operating Cash Flow FY 2023 · Dec 31, 2022 −$26.62M
Short Term Investments FY 2023 · Dec 31, 2023 $999K
Short Term Investments FY 2023 · Dec 31, 2022 $11.35M
Cash And Equivalents FY 2023 · Dec 31, 2023 $35.08M
Cash And Equivalents FY 2023 · Dec 31, 2022 $56.01M
Stockholders Equity FY 2023 · Dec 31, 2023 $27.31M
Stockholders Equity FY 2023 · Dec 31, 2022 $59.58M
Stockholders Equity FY 2023 · Dec 31, 2021 $88.98M
Current Liabilities FY 2023 · Dec 31, 2023 $7.03M
Current Liabilities FY 2023 · Dec 31, 2022 $6.71M
Total Liabilities FY 2023 · Dec 31, 2023 $13.33M
Total Liabilities FY 2023 · Dec 31, 2022 $12.71M
Current Assets FY 2023 · Dec 31, 2023 $40.04M
Current Assets FY 2023 · Dec 31, 2022 $72.01M
Total Assets FY 2023 · Dec 31, 2023 $40.64M
Total Assets FY 2023 · Dec 31, 2022 $72.29M
Eps Diluted FY 2023 · Dec 31, 2023 −$4.18
Eps Diluted FY 2023 · Dec 31, 2022 −$3.71
Eps Basic FY 2023 · Dec 31, 2023 −$4.18
Eps Basic FY 2023 · Dec 31, 2022 −$3.71
Sga Expense FY 2023 · Dec 31, 2023 $16.57M
Sga Expense FY 2023 · Dec 31, 2022 $15.71M
Rd Expense FY 2023 · Dec 31, 2023 $22.1M
Rd Expense FY 2023 · Dec 31, 2022 $17.86M
Net Income FY 2023 · Dec 31, 2023 −$34.03M
Net Income FY 2023 · Dec 31, 2022 −$31.06M
Operating Income FY 2023 · Dec 31, 2023 −$36.61M
Operating Income FY 2023 · Dec 31, 2022 −$32.04M
Revenue FY 2023 · Dec 31, 2023 $2.05M
Revenue FY 2023 · Dec 31, 2022 $1.52M